ALSO NOTED: Wockhardt gets OK for Zithromax copy; Depomed's gabapentin formula passes Phase II;

> Wockhardt got the FDA nod to sell a copycat form of Pfizer's Zithromax, an antibiotic. Report

> Depomed announced that its in-development extended release form of gabapentin showed efficacy against menopausal hot flashes in a Phase II trial. Report

> Nektar Therapeutics' COO Dr. Hoyoung Huh stepped down to take a CEO job at BiPar Sciences; separately, the company said it would cut 150 employees, or about 20 percent of its workforce. Release | Release

> A new study found that the epilepsy med Trileptal didn't prevent migraines; the drug and its ilk have been used against migraine for decades. Report

> An Alabama attorney asked a jury to award the state $40 million in compensatory damages in a fraud lawsuit against AstraZeneca, which alleges that the company inflated its prices. Report

> The FDA has told Adolor and GSK that it will take three more months to review Entereg, a anti-constipation drug candidate. Report

> Italy's Newron Pharmaceuticals has U.K.-based Hunter-Fleming, a company that's developing therapies for neurodegenerative and inflammatory disorders. Report

> An article in the Indianapolis Star details Lilly's development program for MBP9289, a multiple sclerosis drug offering hope to both patients and a drug developer that hasn't launched a new drug for humans since 2005. Report

> Rumors are swirling that Sanofi-Aventis may be making a bid for Oxford BioMedica, a U.K.-based developer of gene-based medicines. Report

And Finally... Just in time for Valentine's Day, more good news about chocolate's health effects. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.